Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Reexamination Certificate
2001-02-28
2003-02-11
Tate, Christopher R. (Department: 1651)
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
C514S006900, C530S380000, C530S385000
Reexamination Certificate
active
06518010
ABSTRACT:
BACKGROUND OF THE INVENTION
The development of hemoglobin-based oxygen carriers has focused on oxygen delivery for use in medical therapies such as transfusions and the production of blood products. Hemoglobin-based oxygen carriers can be used to prevent or treat hypoxia resulting from blood loss (e.g, from acute hemorrhage or during surgical operations), from anemia (e.g., pernicious anemia or sickle cell anemia), or from shock (e.g, volume deficiency shock, anaphylactic shock, septic shock or allergic shock).
Existing hemoglobin-based oxygen carriers include perfluorochemicals, synthesized hemoglobin analogues, liposome-encapsulated hemoglobin, chemically-modified hemoglobin, and hemoglobin-based oxygen carriers in which the hemoglobin molecules are crosslinked. Preparation of hemoglobin-based oxygen carriers includes several purification steps. Among the components that must be removed from collected blood is fibrinogen, which is a soluble protein that is converted into fibrin by the action of thrombin during clotting. Current techniques for processing blood often include addition of chemical agents, such as sodium citrate, to prevent coagulation. However, additional techniques which might, for example, reduce the expense of processing, without diminishing other qualities, such as ultimate product purity, are sought.
SUMMARY OF THE INVENTION
The present invention relates to the use of defibrinated blood for purifying red blood cells, preparing a hemoglobin solution, and preparing a hemoglobin-based oxygen carrier. Chemical clotting agents (such as collagen) and mechanical agitation (such as stirring) are methods used to defibrinate blood. Subsequent cell washing removes plasma proteins that may lead to incompatibility between donor and recipient blood.
In one embodiment, the method for purifying red blood cells includes defibrinating whole blood, the whole blood including red blood cells and a plasma component. Subsequently, the whole blood is filtered to purify the red blood cells and thereby form a red blood cell suspension.
In an embodiment of the method for preparing a hemoglobin solution, whole blood is defibrinated. Red blood cells are separated from the whole blood, and hemoglobin molecules are isolated from the red blood cells to form thereby a hemoglobin solution.
In one embodiment of the method to prepare a hemoglobin-based oxygen carrier, whole blood is defibrinated. Red blood cells are separated from the whole blood. Hemoglobin molecules are isolated and stabilized to form the hemoglobin-based oxygen carrier.
The advantages of this invention are numerous. One advantage is that the invention obviates the need for an anticoagulant solution to be mixed with whole blood (human, bovine, mammalian). Adding an anticoagulant involves manpower and capital for the processes of preparation of high purity water mixing solutions, preparation of citrated collection containers, collection, mixing, and purification. In addition, when shipping blood, generally it is easier to defibrinate blood than it is to build facilities for addition of an anticoagulant at the shipper's location.
REFERENCES:
patent: 3973001 (1976-08-01), Jaeger et al.
patent: 3991181 (1976-11-01), Doczi
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4053590 (1977-10-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4401652 (1983-08-01), Simmonds et al.
patent: 4439357 (1984-03-01), Bonhard et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4826811 (1989-05-01), Sengal et al.
patent: 4857636 (1989-08-01), Hsia
patent: 4861867 (1989-08-01), Estep
patent: 5045529 (1991-09-01), Chiang
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5189146 (1993-02-01), Hsia
patent: 5194590 (1993-03-01), Sehgal et al.
patent: 5264555 (1993-11-01), Shorr et al.
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5691452 (1997-11-01), Gawryl et al.
patent: 5691453 (1997-11-01), Wertz et al.
patent: 5753616 (1998-05-01), Rausch et al.
patent: 5808011 (1998-09-01), Gawryl et al.
patent: 5840852 (1998-11-01), Rausch et al.
patent: 5854209 (1998-12-01), Jacobs, Jr. et al.
patent: 5895810 (1999-04-01), Light et al.
patent: 824 375 (1959-11-01), None
patent: WO 88/03408 (1988-05-01), None
patent: WO 89/06538 (1989-07-01), None
patent: WO 89/12456 (1989-12-01), None
patent: WO 95/22605 (1995-08-01), None
patent: WO 96/29346 (1996-09-01), None
patent: WO 00/21366 (2000-04-01), None
Cheung et al., “The Preparation of Stroma-Free Hemoglobin by Selective DEAE-Cellulose Absorption,”Analytical Biochemistry, 137:481-484 (1984).
Cole et al., “Focal Cerebral Ischemia in Rats: Effect of Hemodilution with &agr;-&agr; Cross Linked Hemoglobin on CBF,”J. Cereb. Blood Flow Metab., 12(6):971-976 (1992).
De Venuto et al., “Characteristics of stroma-free hemoglobin prepared by crystallization,”J. Lab Clin. Med., 89(3): 509-516 (1977).
DeVenuto et al., “Appraisal of Hemoglobin Solution as a Blood Substitute,”Surgery, Gynecology,&Obstetrics, 149(3) :417-436 (1979).
Feola et al., “Development of a Bovine Stroma-Free Hemoglobin Solution as a Blood Substitute,”Surgery, Gynecology&Obstetrics, 157(5) :399-408 (1983).
Gibbs, “Artificial Blood Quickens,”Scientific American, [online] [retrieved on Feb. 14, 2001]. Retrieved from Internet: <URL:http://www.sciam.com/0996issue/0996techbus4.html>.
Hamilton et al., “Preparation of Hemoglobin Solutions for Intravenous Infusion,”J. Exp. Med., 86:455-463 (1947).
Sehgal et al., “Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity,”Surgery, 95:433-438 (1984).
Ritter, “Passing a Blood Test,”Chemical&Engineering, 76:37-44 (1998).
Savitsky et al., “A clinical safety trial of stroma-free hemoglobin,”Clin. Pharmacol. Ther., 23(1) :73-80 (1978).
Sharma et al., “An Isologous Porcine Promoter Permits High Level Expression of Human Hemoglobin in Transgenic Swine,”Bio/Technology,12:55-59 (1994).
Teicher et al., “Oxygenation of tumors by a hemoglobin solution,”J. Cancer Res. Clin Oncol., 120:85-90 (1993).
Bray, P.J. et al., “Defibrination of normal human blood in vitro: a method giving a high recovery of untraumatized cells,”British Journal of Haematology, 35(4) :551-559 (1977). (From Database Medline, 1997, Abstract No. NLM871408.
Kay, H. David et al., “Rapid recovery of non-hemolyzed serum and untraumatized cells by using a new method of blood defibrination in vitro,”J. of Immunological Methods, 92(2): 251-260 (1986).
Topping, David L. et al., “Effects of insulin on the metabolism of the isolated working rat heart perfused with undiluted rat blood,”Biochimica et Biophysica Acta, 844(2):113-118 (1985).
Gawryl Maria S.
Houtchens Robert A.
Light William R.
Biopure Corporation
Srivastava Kailash C.
Tate Christopher R.
LandOfFree
Use of defibrinated blood for manufacture of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of defibrinated blood for manufacture of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of defibrinated blood for manufacture of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3118723